Ani Pharmaceuticals (ANIP) Assets Average (2011 - 2026)
Ani Pharmaceuticals (ANIP) posted Assets Average of $1.4 billion for Q1 2026, little changed sequentially from $1.4 billion in Q4 2025, and up 11.08% YoY from $1.3 billion in Q1 2025.
Ani Pharmaceuticals (ANIP) Assets Average (2011 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $1.4 billion in Q1 2026.
- Quarterly Assets Average rose 11.08% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 11.08% YoY) and the FY2025 annual result came in at $1.4 billion, up 24.49% from the prior year.
- Assets Average steadied at $1.4 billion in Q1 2026 per ANIP's latest filing, from $1.4 billion in the prior quarter.
- Over five years, Assets Average peaked at $1.4 billion in Q1 2026 and troughed at $745.2 million in Q3 2022.
- A 5-year average of $1.0 billion and a median of $909.5 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average surged 63.93% in 2022, then increased 0.58% in 2023.
- Over 5 years, Assets Average stood at $749.6 million in 2022, then climbed by 19.69% to $897.2 million in 2023, then surged by 43.33% to $1.3 billion in 2024, then rose by 10.76% to $1.4 billion in 2025, then gained by 0.49% to $1.4 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $1.4 billion, $1.4 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 5.97 Bn |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 1.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.46 Bn |
| Mar 31, 2026 | 1.43 Bn |
| Dec 31, 2025 | 1.42 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 1.32 Bn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Sep 30, 2024 | 1.10 Bn |
| Jun 30, 2024 | 917.64 Mn |
| Mar 31, 2024 | 909.47 Mn |
| Dec 31, 2023 | 897.17 Mn |
| Sep 30, 2023 | 874.63 Mn |
| Jun 30, 2023 | 812.28 Mn |
| Mar 31, 2023 | 762.66 Mn |
| Dec 31, 2022 | 749.60 Mn |
| Sep 30, 2022 | 745.22 Mn |
| Jun 30, 2022 | 748.09 Mn |
| Mar 31, 2022 | 758.22 Mn |
| Dec 31, 2021 | 621.03 Mn |
| Sep 30, 2021 | 475.31 Mn |